-
Views
-
Cite
Cite
Marco Valgimigli, Sara Ariotti, Francesco Costa, Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus?, European Heart Journal, Volume 36, Issue 20, 21 May 2015, Pages 1219–1222, https://doi.org/10.1093/eurheartj/ehv053
- Share Icon Share
Extract
This editorial refers to ‘ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting’†, by S. Schulz-Schüpke et al., on page 1252.
‘Well? Shall we go?’—‘Yes, let's go’. ‘They do not move.’
Waiting for Godot, by Samuel Beckett,
Combined treatment with aspirin and a P2Y12 inhibitor, the so-called dual antiplatelet therapy (DAPT) regimen, exerts protection against ischaemic myocardial recurrences via a double mechanism of action.
First, it prevents sudden thrombotic occlusion of previously implanted stent(s) in the coronary arteries, thereby reducing the risk of stent thrombosis that occurs as a result of inflammation during healing.1,2 Since the vast majority of stent thrombosis cases are known to occur within the first weeks after stent implantation, an arbitrary 30 day to 6 weeks duration of DAPT has been investigated and a 30 day duration of therapy has become the standard of care approach after uncoated stent implantation.